Key result
Tafamidis and novel TTR-targeting therapies reduce mortality and cardiovascular hospitalizations in transthyretin amyloid cardiomyopathy.
Why the study?
ATTR is an underdiagnosed cause of morbidity and mortality with evolving therapeutic options, warranting an update following recent clinical trials along with practical management recommendations.
What are the current and emerging pharmacological treatments for cardiac transthyretin amyloidosis?
What are the current and emerging pharmacological treatments for cardiac transthyretin amyloidosis?
Answers are grounded in this paper and cite their sources.
This review synthesizes the rapidly evolving landscape of disease-modifying therapies for ATTR cardiomyopathy, highlighting tafamidis as a key breakthrough.
Transthyretin (TTR) is a tetrameric protein synthesized mostly by the liver. As a result of gene mutations or as an ageing-related phenomenon, TTR molecules may misfold and deposit in the heart and in other organs as amyloid fibrils. Cardiac involvement in TTR-related amyloidosis (ATTR) manifests typically as left ventricular pseudohypertrophy and/or heart failure with preserved ejection fraction. ATTR is an underdiagnosed disorder as well as a crucial determinant of morbidity and mortality, thus justifying the current quest for a safe and effective treatment. Therapies targeting cardiac damage and its direct consequences may yield limited benefit, mostly related to dyspnoea relief through diuretics. For many years, liver or combined heart and liver transplantation have been the only available treatments for patients with mutations causing ATTR, including those with cardiac involvement. The therapeutic options now include several pharmacological agents that inhibit hepatic synthesis of TTR, stabilize the tetramer, or disrupt fibrils. Following the positive results of a phase 3 trial on tafamidis, and preliminary findings on patisiran and inotersen in patients with ATTR-related neuropathy and cardiac involvement, we provide an update on this rapidly evolving field, together with practical recommendations on the management of cardiac involvement.
No takes yet. Share an insight, caveat, or question.
Emdin et al. (2019) conducted a review in Cardiac transthyretin amyloidosis (ATTR). Pharmacological therapies (e.g., tafamidis, patisiran, inotersen) was evaluated. Novel pharmacological therapies, particularly the TTR stabilizer tafamidis, have emerged as effective disease-modifying treatments that reduce mortality and cardiovascular hospitalizations in patients with cardiac transthyretin amyloidosis.
Synapse has enriched 10 related papers. Consider them for comparative context: